Experienced in Interstitial Lung Disease

Mingwei Chen

277#, Yanta West Road, 
Xi'an, CN 
Experienced in Interstitial Lung Disease
277#, Yanta West Road, 
Xi'an, CN 
OverviewLocationsClinical Research

Overview

Mingwei Chen practices in Xi'an, China. Chen is rated as an Experienced expert by MediFind in the treatment of Interstitial Lung Disease. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 116 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 7 articles in the study of Interstitial Lung Disease.

Locations

277#, Yanta West Road, Xi'an, 710061, China
Other Locations
No. 277, Yanta West Road, Xi'an, 710061, China
No. 277, West Yanta Road, Xi'an, 710061, China
1# Xin Wang Road, Xi'an, 710021, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Tislelizumab+Cisplatin or Carboplatin+Pemetrexed, Cisplatin or Carboplatin+Pemetrexed
Study Phase: Phase 3

116 Total Publications

Iron status mediates the causal effects of high-altitude adaptation signals in the HIF-PHD axis on pulmonary vascular and right-heart outcomes.
Iron status mediates the causal effects of high-altitude adaptation signals in the HIF-PHD axis on pulmonary vascular and right-heart outcomes.
Journal: Clinical and experimental hypertension (New York, N.Y. : 1993)
Published: December 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chen's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile